IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis

Clinical trial NCT06677710 · SUSPENDED

Trial details

NCT number: NCT06677710
Sponsor: Indapta Therapeutics, INC.
Status: SUSPENDED
Phase: Phase 1
Study type: INTERVENTIONAL

Multiple Sclerosis Primary Progressive Multiple Sclerosis (PPMS)Secondary Progressive Multiple Sclerosis (SPMS)Non-Active Secondary Progressive Multiple Sclerosis Non-Active SPMS Autoimmune Diseases of the Nervous System Nervous System Diseases Autoimmune Diseases Demyelinating Diseases Immune System Diseases Demyelinating Autoimmune Diseases, Central Nervous System (CNS)

Start date: 2026-06-30
Primary completion: 2026-12-31
Enrollment: 34

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.